Does ChAdOx1-S and BNT162b2 heterologous prime-boost vaccination trigger higher rates of vaccine-related adverse events?
Adverse events
COVID-19 vaccination
Heterologous
Homologous
Prime-post vaccination
Journal
IJID regions
ISSN: 2772-7076
Titre abrégé: IJID Reg
Pays: England
ID NLM: 9918418183106676
Informations de publication
Date de publication:
Jun 2023
Jun 2023
Historique:
received:
31
10
2022
revised:
08
03
2023
accepted:
08
03
2023
medline:
8
4
2023
entrez:
7
4
2023
pubmed:
8
4
2023
Statut:
ppublish
Résumé
There has been significant international interest in heterologous prime-boost COVID-19 vaccination. However, it is linked with different intensity and frequency of adverse events. This study aimed to assess the safety of ChAdOx1-S and BNT162b2 vaccines when given as heterologous prime-boost vaccination in Saudi Arabia. A cross-sectional study was conducted during the period October 2021 to March 2022. The study included two groups of people based on the type of vaccination regimen. The first group (heterologous) was subjected to different prime-boost vaccination schedules irrespective of the prime and boost vaccine types. The second group included people vaccinated with the same type of COVID-19 vaccine (homologous). The overall sample included 334 participants. Those included in the heterologous group were at about 1.5 fold -increased risk for developing local and systemic adverse events compared to the homologous group. Fever, headache, and vomiting were significantly more frequent among the heterologous group compared to the homologous group (p-value<0.05). In both groups, more than half of the recorded adverse events were mild/moderate in severity. Heterologous prime-post vaccination is associated with a slightly increased risk for the development of local and systemic adverse events compared to the homologous regimen. However, most of these adverse events are mild/moderate in nature and recede within two days with no serious adverse events documented.
Sections du résumé
Background
UNASSIGNED
There has been significant international interest in heterologous prime-boost COVID-19 vaccination. However, it is linked with different intensity and frequency of adverse events. This study aimed to assess the safety of ChAdOx1-S and BNT162b2 vaccines when given as heterologous prime-boost vaccination in Saudi Arabia.
Methods
UNASSIGNED
A cross-sectional study was conducted during the period October 2021 to March 2022. The study included two groups of people based on the type of vaccination regimen. The first group (heterologous) was subjected to different prime-boost vaccination schedules irrespective of the prime and boost vaccine types. The second group included people vaccinated with the same type of COVID-19 vaccine (homologous).
Results
UNASSIGNED
The overall sample included 334 participants. Those included in the heterologous group were at about 1.5 fold -increased risk for developing local and systemic adverse events compared to the homologous group. Fever, headache, and vomiting were significantly more frequent among the heterologous group compared to the homologous group (p-value<0.05). In both groups, more than half of the recorded adverse events were mild/moderate in severity.
Conclusion
UNASSIGNED
Heterologous prime-post vaccination is associated with a slightly increased risk for the development of local and systemic adverse events compared to the homologous regimen. However, most of these adverse events are mild/moderate in nature and recede within two days with no serious adverse events documented.
Identifiants
pubmed: 37025346
doi: 10.1016/j.ijregi.2023.03.003
pii: S2772-7076(23)00028-0
pmc: PMC10005969
doi:
Types de publication
Journal Article
Langues
eng
Pagination
159-163Informations de copyright
© 2023 Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
Déclaration de conflit d'intérêts
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
Références
Lancet Respir Med. 2021 Nov;9(11):1255-1265
pubmed: 34391547
Nature. 2021 May;593(7860):491
pubmed: 34012131
Hum Vaccin Immunother. 2022 Dec 31;18(1):2039017
pubmed: 35240939
Springer Semin Immunopathol. 2006 Nov;28(3):255-65
pubmed: 17021720
Saudi Med J. 2022 Apr;43(4):386-393
pubmed: 35414617
Lancet. 2021 May 29;397(10289):2043-2046
pubmed: 33991480
Travel Med Infect Dis. 2021 Sep-Oct;43:102119
pubmed: 34133965
Int J Infect Dis. 2021 Sep;110:359-362
pubmed: 34320413
Immunol Today. 2000 Apr;21(4):163-5
pubmed: 10740236
Lancet Infect Dis. 2022 Apr;22(4):438-440
pubmed: 35278358
Expert Rev Vaccines. 2021 Oct;20(10):1211-1220
pubmed: 34415818
Infect Dis Poverty. 2022 May 13;11(1):53
pubmed: 35562753
Vaccines (Basel). 2021 Aug 04;9(8):
pubmed: 34451982
Prev Med Rep. 2021 Oct 11;24:101595
pubmed: 34976653
EBioMedicine. 2022 Jan;75:103761
pubmed: 34929493
Lancet Glob Health. 2021 May;9(5):e590-e592
pubmed: 33667404
Vaccines (Basel). 2022 May 11;10(5):
pubmed: 35632510
Lancet. 2021 Dec 19;396(10267):1979-1993
pubmed: 33220855